US regulatory status: approved. Molecular target: Vitamin D3 receptor.
- Target
- Vitamin D3 receptor
- Mechanism
- Vitamin D receptor agonist
pharma · Skin Toxicities Associated with Epidermal Growth Factor Receptor Inhibitors · Atopic Dermatitis · HOTH
Hoth Therapeutics
Hoth Therapeutics drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Norwich, GB HQ
12 Employees
Public company Type
HOTH · NYSE Ticker
Company details
- Status
- Public
- HQ
- Norwich, GB
- Employees
- 12
- Programs
- 3
- Drugs
- 4
- Patents
- 1
Hoth Therapeutics pipeline
Portfolio lens on 4 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Hoth Therapeutics drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Hoth Therapeutics in public FDA and regional records.
-
Development asset linked to Hoth Therapeutics in public FDA and regional records.
-
Development asset linked to Hoth Therapeutics in public FDA and regional records.